Marshall Wace’s C4 Therapeutics CCCC Stock Holding History

Marshall Wace’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$409K	Sell	155,495 -109,532	-41%	-$258K	﹤0.01%	2536
2025 Q4	$506K	Buy	265,027 +158,752	+149%	+$376K	﹤0.01%	2231
2025 Q3	$236K	Buy	+106,275	New	+$255K	﹤0.01%	2523
2025 Q1	–	Sell	-36,167	Closed	-$130K	–	2657
2024 Q4	$130K	Sell	36,167 -189,249	-84%	-$941K	﹤0.01%	2419
2024 Q3	$1.28M	Buy	+225,416	New	+$1.36M	﹤0.01%	1544
2024 Q2	–	Sell	-146,644	Closed	-$1.2M	–	2578
2024 Q1	$1.2M	Sell	146,644 -976,417	-87%	-$7.57M	﹤0.01%	1580
2023 Q4	$6.35M	Buy	+1,123,061	New	+$2.56M	0.01%	827
2023 Q2	–	Sell	-113,236	Closed	-$356K	–	2507
2023 Q1	$356K	Buy	+113,236	New	+$667K	﹤0.01%	2240
2022 Q3	–	Sell	-252,326	Closed	-$1.9M	–	3376
2022 Q2	$1.9M	Buy	+252,326	New	+$2.22M	﹤0.01%	2036

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace's CCCC Position: Q1 2026 in Review

Marshall Wace reduced its C4 Therapeutics (CCCC) stake by 41% in Q1 2026, selling an estimated $258K and leaving 155,495 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Marshall Wace first reported a position in CCCC in Q2 2022 and has held it in 9 quarters since. The position peaked at $6.35M in Q4 2023. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Marshall Wace held 155,495 shares of C4 Therapeutics worth $409K as of Q1 2026.
Marshall Wace sold 109,532 C4 Therapeutics shares in Q1 2026, an estimated $258K.
C4 Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2536 holding.
Marshall Wace first reported a position in C4 Therapeutics in Q2 2022 and has held it in 9 quarters since.
Marshall Wace's C4 Therapeutics position peaked at $6.35M in Q4 2023.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.